Skip to ContentSkip to Navigation
About us Faculty of Law Research Centres of Expertise Global Health Law Groningen Research Centre
Header image Global Health Law Groningen

Dolutegravir Patent Licences Can Provide Access To All

Date:28 July 2017
Author:GHLG Blog
This year the World Health Organization (WHO) added dolutegravir, an antiretroviral medicine for the treatment of HIV infection, to its Model List of Essential Medicines in response to the recent evidence showing the medicine’s safety, efficacy, and high barrier to resistance. A recent study HIV drug resistance report 2017 launched by the WHO at the IAS2017 shows that in 6 of the 11 countries surveyed in Africa, Asia and Latin America, over 10% of people starting antiretroviral therapy had a strain of HIV that was resistant to some of the most widely used HIV medicines. This is a worrying trend and such levels of resistance demand a review of the treatment practices including switching to more robust ARV regimen.

.

Date:25 July 2017
Author:GHLG Blog

.

Voices in the Field: Dr Tankred Stoebe

Date:22 July 2017
Author:GHLG Blog

Interview conducted  April 15th 2017 by Helena Lindemann. Photo by Barbara Sigge.

Voices in the Field: Ellen ‘t Hoen

Date:01 July 2017
Author:GHLG Blog

Ellen ‘t Hoen is a lawyer and public health advocate with over 30 years of experience working on pharmaceutical and intellectual property policies. She has also published widely, her latest book being “Private Patents and Public Health: Changing...

The Most Common Misunderstanding About Compulsory Licences

Date:01 June 2017
Author:GHLG Blog
The belief that a country can only use compulsory licensing in cases of public health emergencies is a myth that has proven difficult to bust.

Seeking a French-speaking legal researcher for short-term case study (June-July 2017)

Date:30 May 2017
Author:GHLG Blog

Seeking legal research experience? Fluent in French? Interested in human rights and health?

A New Access to Medicines Initiative: Medicines Law & Policy

Date:26 May 2017
Author:GHLG Blog
This week during the WHO’s 70th World Health Assembly, GHLG member Ellen ‘t Hoen announced the launch of the new website, ‘Medicines Law & Policy’, established with colleagues Pascale Boulet and Kaitlin Mara, all experts in intellectual property and access to medicines. ML&P provides expertise in the form of policy and legal analyses, best practice models, and other information to work toward the goal of ensuring the availability of effective, safe, and affordable medicines for all.

Vision for sustainable access to innovative medicines: GHLG & UMCG’s Global Health Unit respond to the OECD

Date:11 May 2017
Author:GHLG Blog
Excessively high prices of innovative medicines threaten patient access and health system sustainability in developing and industrialised countries alike. The Organisation for Economic Co-operation and Development (OECD) has launched a new initiative to facilitate high-level dialogue between stakeholders on access to innovative medicines and the sustainability of prices. On April 30, 2017, members of the GHLG Research Centre and the Global Health Unit in the Dept. of Health Sciences at the University Medical Centre Groningen responded to OECD’s online consultation for sustainable access to innovative medicines. Below are excerpts from our response.

The Italian Exception: A personalised approach to accessing high-priced patented medicines

Date:10 May 2017
Author:GHLG Blog
At the end of March 2017, the Italian Minister of Health Beatrice Lorenzin authorised the importation of generic medicines. She did this with only a veiled reference to the high-priced hepatitis C (HCV) medicine sofosbuvir, marketed under the trade name Sovaldi. However, the authorisation is not restricted to the treatment of HCV and can be used to find alternatives for any medicine not available or affordable in Italy.

Monitoring needed for improving access to health care of irregular migrants

Date:02 May 2017
Author:GHLG Blog
Irregular migrants face obstacles when trying to obtain health care. In order to enjoy the right to health, it is necessary to create a central reporting point to monitor actual obstacles in the access of health care of irregular migrants.